Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16^INK4a)/ARF (p14^ARF) locus in urinary bladder cancer

References

• Cairns P, Shaw ME, Knowles MA. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 1993; 8: 1083–5
   PubMed Web of Science ®Google Scholar
• Cairns P, Shaw ME, Knowles MA. Preliminary mapping of the deleted region of chromosome 9 in bladder cancer. Cancer Res 1993; 53: 1230–2
   PubMed Web of Science ®Google Scholar
• Tsai YC, et al. Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res 1990; 50: 44–7
   PubMed Web of Science ®Google Scholar
• Cairns P, et al. Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res 1994; 54: 1422–4
   PubMed Web of Science ®Google Scholar
• Devlin J, Keen AJ, Knowles MA. Homozygous deletion mapping at 9p21 in bladder carcinoma defines a critical region within 2cM of IFNA. Oncogene 1994; 9: 2757–60
   PubMed Web of Science ®Google Scholar
• Quelle DE, et al. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993–1000
   PubMed Web of Science ®Google Scholar
• Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704–7
   PubMed Web of Science ®Google Scholar
• Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998; 1378: F115–77
   PubMed Web of Science ®Google Scholar
• Cairns P, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995; 11: 210–2
   PubMed Web of Science ®Google Scholar
• Orlow I, et al. Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 1995; 87: 1524–9
   PubMed Web of Science ®Google Scholar
• Sakano S, et al. Clinical course of bladder neoplasms and single nucleotide polymorphisms in the CDKN2A gene. Int J Cancer 2003; 104: 98–103
   PubMed Web of Science ®Google Scholar
• Williamson MP, et al. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 1995; 4: 1569–77
   PubMed Web of Science ®Google Scholar
• Florl AR, et al. DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder. Lab Invest 2000; 80: 1513–22
   PubMed Web of Science ®Google Scholar
• Gonzalez-Zulueta M, et al. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995; 55: 4531–5
   PubMed Web of Science ®Google Scholar
• Gonzalgo ML, et al. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res 1998; 58: 1245–52
   PubMed Web of Science ®Google Scholar
• Merlo A, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995; 1: 686–92
   PubMed Web of Science ®Google Scholar
• Orlow I, et al. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol 1999; 155: 105–13
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9: 1149–63
   PubMed Web of Science ®Google Scholar
• Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323–30
   PubMed Web of Science ®Google Scholar
• Heney NM. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am 1992; 19: 429–33
   PubMed Web of Science ®Google Scholar
• Gardie B, et al. Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia. Blood 1998; 91: 1016–20
   PubMed Web of Science ®Google Scholar
• Ichimura K, et al. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 2000; 60: 417–24
   PubMed Web of Science ®Google Scholar
• Kumar R, et al. Selective deletion of exon 1 beta of the p19ARF gene in metastatic melanoma cell lines. Genes Chromosomes Cancer 1998; 23: 273–7
   PubMed Web of Science ®Google Scholar
• Berggren P, et al. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR.@. Clin Cancer Res 2003; 9: 235–42
   PubMed Web of Science ®Google Scholar
• Larsson P, et al. A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand J Urol Nephrol 2003; 37: 195–201
   PubMed Web of Science ®Google Scholar
• Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. A laboratory manual2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989
   Google Scholar
• Bergkvist A, Ljungqvist A, Moberger G. Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years. Acta Chir Scand 1965; 130: 371–8
   PubMedGoogle Scholar
• Carbin, BE, et al. Grading of human urothelial carcinoma based on nuclear atypia and mitotic frequency. II. Prognostic importance, 2nd ed. Springer: Berlin. J Urol 1991;145:972–5; discussion 975–6.
   PubMed Web of Science ®Google Scholar
• Mostofi FK, Davies CJ, Sesterhenn IA. Histological typing of urinary bladder tumours. In: International classification of tumours. WHO, GenevaSwitzerland 1999
   Google Scholar
• International Union Against Cancer. TNM classification of malignant tumours. GenevaSwitzerland: WHO; 1978.
   Google Scholar
• Kibel AS, et al. Deletion mapping at 12p12-13 in metastatic prostate cancer. Genes Chromosomes Cancer 1999; 25: 270–6
   PubMed Web of Science ®Google Scholar
• Aveyard JS, Knowles MA. Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification. J Mol Diagn 2004; 6: 356–65
   PubMed Web of Science ®Google Scholar
• Christopher SA, et al. Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. Cancer Res 2002; 62: 6639–44
   PubMed Web of Science ®Google Scholar
• Peters KG, et al. Functional significance of Tie2 signaling in the adult vasculature. Recent Prog Horm Res 2004; 59: 51–71
   PubMedGoogle Scholar